FDA Approves Gilead's Twice-Yearly Shot for HIV Prevention

Key Takeaways GILD received FDA approval for Yeztugo, a twice-yearly injectable HIV-1 capsid inhibitor for PrEP use. Yeztugo showed superior HIV prevention in late-stage studies, outperforming daily oral Truvada. Yeztugo's long-acting dosing aims to boost PrEP uptake by reducing adherence challenges and stigma.Gilead Sciences, Inc. (GILD) obtained FDA approval for its twice-yearly injectable HIV-1 capsid inhibitor, lenacapavir, for the prevention of HIV.The regulatory body approved lenacapavir, under the ...